SEC Form 4 · accession 0001246842-26-000008
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A Goldsmith
Officer — See Remarks · Director
Period of report
Sep 16, 2026
Accepted (ET)
Sep 18, 2026 · 6:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Sep 16, 2026 | S | 213 | $195.0085 | D | 267,117 | D | |
| Common StockF3 | Sep 16, 2026 | S | 13,775 | $199.3032 | D | 253,342 | D | |
| Common StockF4 | holding | — | — | — | 594,060 | I | Trust | |
| Common StockF5 | holding | — | — | — | 61,424 | I | Trust | |
| Common StockF6 | holding | — | — | — | 61,424 | I | Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
- F2The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 157,588 restricted stock units.
- F4Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
- F5Held by Jonathan Goldsmith Revocable Trust.
- F6Held by Rebecca Goldsmith Revocable Trust.
Remarks
President and Chief Executive Officer